Eravacycline Conference Call: Unrevealing and Disappointing
Whatever has become of investigative journalism? All we read after the Stifel conference call (11/17/2015) is descriptive rehash of information provided by Tetraphase at the conference. No probing questions that we thought investors would ask who just lost 80% of their money. No signs of analytical or strategic readjustment at Continue reading Eravacycline Conference Call: Unrevealing and Disappointing